Search

DECIPHER BIOSCIENCES ANNOUNCES PUBLICATION OF A PROSPECTIVE CLINICAL STUDY DEMONSTRATING THAT THE USE OF DECIPHER PROSTATE RP GUIDES POST-OPERATIVE MANAGEMENT DECISIONS AND IMPROVES PATIENT OUTCOMES

SAN DIEGO, Dec. 16, 2019 /PRNewswire/ - Decipher Biosciences, a commercial stage precision oncology company initially focused on urologic...

PREDICTING ASSOCIATIONS AMONG DRUGS, TARGETS AND DISEASES BY TENSOR DECOMPOSITION FOR DRUG REPOSITIONING

Abstract Background Development of new drugs is a time-consuming and costly process, and the cost is still increasing in recent years....

 
 
 

APPLICATION OF RAMAN SPECTROSCOPY IN MONOCLONAL ANTIBODY PRODUCING CONTINUOUS SYSTEMS FOR DOWNSTREAM PROCESS INTENSIFICATION

Abstract Monoclonal antibodies are biopharmaceuticals produced by mammalian cell lines in bioreactors at a variety of scales. Cell...

METABOLIC ENGINEERING FOR THE PRODUCTION OF FAT-SOLUBLE VITAMINS: ADVANCES AND PERSPECTIVES

Abstract Fat-soluble vitamins are vitamins that are insoluble in water, soluble in fat, and organic solvents; they are found in minute...

 
 
 

PROJECT MANAGER- DELTA V - PHARMACEUTICAL INDUSTRY - USDM LIFE SCIENCES - OCEANSIDE, CA

? Provides strong project team leadership and champions project team collaboration. And execution according to cost, schedule, quality,...

Bio Roundup: Sarepta's Approval, Merck M&A, Drug Price Bill & More

BIO ROUNDUP: SAREPTA'S APPROVAL, MERCK M&A, DRUG PRICE BILL & MORE

If you're keeping track, FDA drug approvals have been on a tear in the past month with several decisions coming well ahead of their...

 
 
 

SENHWA BIOSCIENCES REPORTS POSITIVE PHASE 1 DATA OF CX-5461 IN PATIENTS WITH ADVANCED SOLID TUMORS AT 2019 SABCS

Evidence of human efficacy observed in patients with specific biomarkers and refractory to standard treatments including platinum and...

DATA FROM PHASE 3 TRIAL EVALUATING FIXED-DOSE SUBCUTANEOUS COMBINATION OF PERJETA® AND HERCEPTIN® USING HALOZYME'S ENHANZE® DRUG DELIVERY TECHNOLOGY TO BE PRESENTED AT SAN ANTONIO BREAST CANCER SYMPOSIUM

Data from Primary Analysis to be Presented in a Spotlight Session Today - Data Expected to be Submitted to U.S. Food and Drug Administration...

 
 
 

MANAGER, ALLIANCE MANAGEMENT - NEUROCRINE BIOSCIENCE - SAN DIEGO, CA

Deliver the value of the deal and maximize relationship with outside pharmaceutical companies, biotechnology companies, and academic...

PROMETHEUS BIOSCIENCES APPOINTS DR. THIERRY DERVIEUX AS CHIEF DEVELOPMENT OFFICER

SAN DIEGO, Dec. 10, 2019 /PRNewswire/ - Prometheus Biosciences, Inc., a biopharmaceutical company committed to the discovery, development,...

 
 
 

GENOME MINING INTEGRATING SEMI-RATIONAL PROTEIN ENGINEERING AND NANOREACTOR DESIGN: ROADMAP FOR A ROBUST BIOCATALYST FOR INDUSTRIAL RESOLUTION OF VINCE LACTAM

Abstract Biomanufacturing of chemicals using biocatalysts is an attractive strategy for the production of valuable pharmaceuticals...

LAB SCIENTIST - EMERALD HEALTH PHARMACEUTICALS - SAN DIEGO, CA

Develops and maintains systems for tracking projects and continuous improvement activities. Emerald Heath Pharmaceuticals is a biotech...

 
 
 
Zentalis Steps Out With $147M Raised to Develop “Tried and True” Small Molecules

ZENTALIS STEPS OUT WITH $147M RAISED TO DEVELOP “TRIED AND TRUE” SMALL MOLECULES

Zentalis Pharmaceuticals is banking on small molecules for cancer-leaving the “cool technologies” aside for a “tried and true” approach,...

Aurinia Plans FDA Filing After Lupus Nephritis Drug Hits Phase 3 Goals

AURINIA PLANS FDA FILING AFTER LUPUS NEPHRITIS DRUG HITS PHASE 3 GOALS

Aurinia shares spiked last week after voclosporin, an immunosuppressant being tested in patients with lupus nephritis, met its primary...

 
 
 
FDA Puts Partial Hold on Tests of Ipsen Drug Acquired in $1B Deal

FDA PUTS PARTIAL HOLD ON TESTS OF IPSEN DRUG ACQUIRED IN $1B DEAL

Two clinical trials testing an Ipsen drug in rare connective tissue disorders have been placed on partial hold after safety concerns...

DECIPHER BIOSCIENCES ACHIEVES MAJOR MEDICARE MILESTONE FOR DECIPHER PROSTATE GENOMIC TESTS

First Precision Oncology Company to Receive Medicare Coverage for Both Favorable and Unfavorable Intermediate Risk Prostate Cancer SAN...

 
 
 

A NEW WAY TO CONTROL MICROBIAL METABOLISM

Microbes can be engineered to produce a variety of useful compounds, including plastics, biofuels, and pharmaceuticals. However, in...

Neurocrine Inks $50M Xenon Pharma Deal to Expand Into Epilepsy

NEUROCRINE INKS $50M XENON PHARMA DEAL TO EXPAND INTO EPILEPSY

Neurocrine Biosciences is paying $30 million cash and taking a $20 million equity stake in Xenon Pharmaceuticals to license a clinical-stage...

 
 
 

NEUROCRINE BIO TAKES AIM AT EPILEPSY WITH $50 MILLION ACQUISITON

Collaboration with Xenon Pharmaceuticals seeks to commercialize treatment for the disease...

EVOFEM BIOSCIENCES REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 2B STUDY OF AMPHORA® FOR PREVENTION OF CHLAMYDIA AND GONORRHEA IN WOMEN

AMPREVENCE Study Met Primary and Secondary Endpoints - a 50% Relative Risk Reduction in Chlamydia Infection and a 78% Relative Risk...